Evaluation of the Clinical Safety and Efficacy of the 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Subjects According to the Indication for Use
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2018
At a glance
- Drugs Zotarolimus (Primary)
- Indications Arteriosclerosis; Cardiovascular disorders; Coronary artery disease; Ischaemic heart disorders
- Focus Therapeutic Use
- 12 Jun 2018 Planned primary completion date changed from 30 May 2018 to 31 Jul 2018.
- 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2017 New trial record